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Background: Immunization of VZV-seronegative solid organ transplant (SOT) patients using 
the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable 
immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for 
VZV seropositive persons to prevent shingles but could potentially also protect VZV-
seronegative persons against varicella. We performed a safety and immunogenicity evaluation 
of RZV in VZV-seronegative SOT recipients as an option for protection.   
Methods: VZV-seronegative adult SOT patients with no history of varicella/shingles vaccine 
or disease were given 2 doses of RZV vaccine 2-6 months apart. Blood was drawn 
prevaccination (V1), prior to the second dose (V2) and 4 weeks after second dose (V3). 
Humoral (anti-gE) and cell-mediated immunity was evaluated, with polyfunctional cells 
defined as cells producing ≥2 cytokines.  
Results: Among 31 eligible VZV-seronegative SOT patients screened, 23 were enrolled. 
Median age was 38 years and median time since transplant procedure was 3.8 years. The most 
frequent transplant types were liver (35%) and lung (30%). Median anti-gE levels 
significantly increased from V1 to V3 (p=0.001) and V2 to V3 (p<0.001), even though only 
55% had a positive seroresponse. Median polyfunctional CD4 T-cells counts increased from 
V1 to V2 (54/106 vs 104/106 cells; p=0.041), and from V2 to V3 (380/106; p=0.002). Most 
adverse events were mild with no rejection episodes.   
Conclusion: RZV was safe and elicited significant humoral and cellular responses in VZV-
seronegative SOT patients, and has the potential to be considered as a preventive strategy 












Solid organ transplant (SOT) recipients are at increased risk for severe or complicated 
primary varicella infection (chickenpox) because of the lifelong immunosuppression essential 
to preventing organ rejection.1,2 Compared to transplanted children, adult seronegative SOT 
recipients seem to have an increased rate of complications and mortality when exposed to 
varicella-zoster virus (VZV).3 Similarly, SOT patients are at increased risk for complicated 
shingles (herpes zoster [HZ] and postherpetic neuralgia in case of VZV reactivation.4,5 
The current vaccine for preventing primary VZV infection is a live-attenuated virus vaccine. 
Because of the risk of vaccine-induced chickenpox, the Infectious Diseases Society of 
America (IDSA) and the American Society of Transplantation (AST) both contraindicate the 
live varicella vaccine after SOT, but emphasize the importance of immunizing seronegative 
candidates with the live vaccine at least 4 weeks prior to SOT.6,7 Unfortunately, optimizing 
VZV immunization prior to SOT is not always feasible because of the urgency of some 
transplants or if the candidate is already immunosuppressed for underlying conditions. 
Therefore, many transplanted patients are left unvaccinated against primary varicella 
infection.   
Shingrix (GSK Vaccines) is recommended by the US Centers for Disease Control and 
Prevention’s Advisory Committee on Immunization Practices (ACIP) for the prevention of 
shingles in persons ≥50 years of age. Shingrix is a nonlive, recombinant subunit zoster 
vaccine (RZV) that contains 50µg lyophilized varicella zoster virus glycoprotein E (gE) 
antigen with the accompanying AS01B adjuvant. The vaccine has been shown to be effective 
in preventing zoster in adults ≥50 years old in a large phase III randomized controlled trial, 
with an overall vaccine efficacy of 97.2%.8 Because it is a subunit vaccine containing only a 
single viral protein (gE), it has also been studied in VZV seropositive immunocompromised 
populations. In a placebo-controlled RCT, the vaccine has been shown to induce cellular and 
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immunogenic in persons living with HIV and is efficacious in preventing shingles in 
seropositive autologous stem cell transplants.10,11  
RZV has been shown to induce humoral and cellular immunity,9-13 both of which should 
contribute to also protect against primary VZV infection. Although the primary indication for 
this vaccine is to boost immunity in VZV IgG-positive persons, we hypothesized that the 
vaccine should be able to induce immunity in VZV IgG-negative patients. To date, there are 
limited data about RZV among VZV IgG-negative patients. The aim of our study was to 
evaluate whether RZV elicited cellular and humoral immunity in a cohort of VZV-
seronegative SOT patients and to determine the feasibility of this approach. RZV could be an 
option to optimize protection against VZV among SOT patients who had not received the live 
VZV vaccine before SOT. This could also be applied to other immunosuppressed cohorts who 
cannot receive the live vaccine. 
MATERIALS AND METHODS 
2.1 Patient population and study design 
This prospective interventional study was conducted starting June 2018, at the University 
Health Network Transplant Centre, a tertiary care organ transplant program in Toronto, 
Canada. Inclusion criteria were 1) age ≥ 18 years old, 2) history of organ transplantation 
(kidney, liver, heart, lung, pancreas, intestine or combined) 3) functioning allograft, 4) at least 
90 days following transplant and 5) negative VZV IgG at time of transplant and confirmed 
prior to vaccination. Exclusion criteria were 1) prior history of shingles or chickenpox 
(occurring either before or after SOT), 2) positive or equivocal VZV IgG at any time before or 
after SOT, 3) prior VZV or HZ immunization, 5) ongoing CMV viremia > 200 IU/mL, 6) 
other immunodeficiency such as HIV positive, 8) treatment for rejection in the past 30 days, 
9) immunoglobulin (eg IVIg) in the past 30 days or anticipated to receive immunoglobulin. 
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(#215830) due to off-label use of RZV. The study was registered at clinicaltrials.gov 
(NCT03685682). 
After obtaining consent, participants received 2 intramuscular 0.5mL doses of RZV 2 to 6 
months apart. Serum and PBMCs were collected prior to first dose of vaccine (V1), prior to 
second dose of vaccine (V2), and 4 weeks after the second dose (V3) (Figure 1). A negative 
prevaccination serostatus was confirmed by the VIDAS ELFA (enzyme linked fluorescent 
assay) VZV IgG assay (VIDAS, Biomerieux, France). Patients were followed up to 3 months 
after the second vaccine dose. 
2.2 Outcomes 
The primary outcomes were gE-specific cellular and humoral immunogenicity. The secondary 
outcome was the safety of the vaccine in the VZV-IgG negative SOT population. A positive 
seroresponse was defined as an antibody level (based on optical density; see below) greater 
than 2 standard deviations above the mean prevaccination value.  
2.3 Humoral immunity 
Sera from all 3 time-points were used for evaluation of humoral immunity using 2 enzyme-
linked immunosorbent assays (ELISA), one specifically targeting VZV glycoprotein E (anti-
gE) and the other a gpELISA (using lentil lectin-purified VZV glycoproteins (gp) including 
gE, gB, gH).14 Both gpELISA and gE ELISA assays were performed at the VZV reference 
laboratory at the Centers for Disease Control and Prevention (CDC, Atlanta, USA).  Samples 
were tested in duplicate. Results for gpELISA were expressed as adjusted optical density 
(OD) values (mean test OD – mean normal tissue control OD). Cut-off point and performance 
specifications for gpELISA were determined on prevaricella and postvaricella serum samples 
from 12-18-month old children (preimmunization = true negative; postimmunization [>3 
weeks] = true positive). Since the gE ELISA utilizes a highly purified glycoprotein E as the 
target antigen, no normal tissue control was required. gE ELISA was compared with 
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strength of antibody) was determined as follows: 2 identical ELISA run plates were prepared, 
1 of which was washed using phosphate buffered saline (PBS) and the other with PBS 
containing diethylamine (DEA). The avidity index (%) was calculated using the OD of wells 
washed with PBS-DEA divided by the OD of wells washed with PBS alone, multiplied by 
100 (Range of results: high avidity ≥ 60, moderate avidity 30 to 59; low avidity ≤29). For 
statistical purposes, a positive seroresponse was defined as an OD value greater than 2 
standard deviations above the mean of prevaccination values.  
2.4 Cellular immunity 
Evaluation of gE-specific cellular immunity was performed using intracellular cytokine 
staining and flow cytometry. Peripheral blood mononuclear cells (PBMCs) were extracted 
from whole blood using Ficoll gradient centrifugation (GE Healthcare Life Science, Issaquah, 
WA, USA) and cryopreserved in fetal bovine serum (Gibco, Thermo Fisher Scientific, 
Waltham, MA, USA) with 10% dimethyl sulfoxide (DMSO) (Fisher BioReagents, Thermo 
Fisher Scientific). To determine vaccine-associated responses, 1x106 PBMCs were stimulated 
immediately after thawing with 1.25 µg/mL of a VZV peptide pool (JPT Peptide 
Technologies, Berlin, Germany) or with media alone for 2 hours. As VZV peptides were 
reconstituted with DMSO, DMSO was added at the same concentration to the unstimulated 
specimens as a negative control. The BD FastImmune anti-human CD28/CD49d 
costimulatory reagent (BD Biosciences, Mississauga, Canada) was added at the same time as 
the antigen. After 2 hours of incubation at 37ºC, Brefeldin A Solution (protein transport 
inhibitor) (BioLegend, San Diego, CA) was added at a concentration of 1 ug/mL for another 
18 hours. Following stimulation, cells were centrifuged and stained with the Zombie Aqua 
viability dye (BioLegend). Following Fc receptor blocking using Human BD Fc Block (BD 
Biosciences), cells were incubated with a cell-surface cocktail consisting of mouse anti-
human CD45 (clone HI30)-PerCP/Cy5.5 (Biolegend), mouse anti-human CD3 (clone OKT3)-
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(BD Pharmingen, BD Biosciences) and mouse anti-human CD8 (clone SK1)-APC-Cy7 (BD 
Pharmingen, BD Biosciences). Following incubation with fixation buffer (BioLegend) cells 
were treated with an intracellular cytokine antibody cocktail prepared in permeabilization 
wash buffer (BioLegend). The intracellular cocktail consisted of mouse anti-human interferon 
(IFN)-γ (clone B27)-FITC (BD Pharmingen, BD Biosciences), mouse anti-human tumor-
necrosis factor (TNF)-α (clone MAb11)-PE-Cy7 (BD Pharmingen, BD Biosciences), rat anti-
human interleukin (IL)-2 (clone MQ1-17H12)-APC (BD Pharmingen, BD Biosciences) and 
mouse anti-human CD154 (CD40L) (clone 24-31)-PE (BD Pharmingen, BD Biosciences). 
Flow cytometry was performed on a BD LSR II (BD Biosciences) at The SickKids-UHN 
Flow and Mass Cytometry Facility (Toronto, ON, Canada) with a target event count of 
100 000 live, CD45+ cells. Data were analyzed using FlowJo software v10 (FlowJo LLC, 
Ashland, OR). To account for background cytokine production, the frequency of cytokine-
producing T-cells obtained in the unstimulated specimen was subtracted from the frequency 
obtained in the stimulated specimen. Cells producing at least 2 cytokines among TNF-α, IFN-
γ, IL-2 and CD40L were considered polyfunctional and were determined as previously 
described.15 A representative gating strategy for the identification of cytokine-producing 
CD4+ and CD8+ T-cells is presented in Figure S1 http://links.lww.com/TP/C105 .    
2.5 Safety 
Patients were provided questionnaires to complete regarding local (pain, redness, swelling) 
and systemic (fever, fatigue, headache, myalgia, gastrointestinal symptoms) adverse events 
during the first 7 days after each vaccine dose. Adverse events were categorized as mild (no 
interference with daily activities), moderate (some interference in daily activities) and severe 
(significant interference with daily activities). Other adverse events were recorded using chart 
review. Biopsy-proven or clinically-treated episodes of rejection were recorded via chart 
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2.6 Statistical Analysis  
Analyses were performed in patients for which both baseline and postvaccine specimens were 
available, per-protocol. For group comparisons, Chi-squared or Fisher exact test were used for 
dichotomous variables, whereas Mann-Whitney U test was used for continuous variables. For 
paired analysis, the Wilcoxon signed rank test was used and Kruskal-Wallis test was used to 
compare across mycophenolate dosing groups. Correlations were determined using Spearman 
coefficient. A line of best fit was generated using simple linear regression to show the 
relationship between humoral and cellular immunity.  P-values <0.05 were considered 
statistically significant. Statistics were performed using SPSS version 23.0 (IBM Corp., 
Armonk, NY). Figures were made using GraphPad version 7.0 (La Jolla, CA) or National 
Institutes of Health (NIH)’s Simplified presentation of incredibly complex evaluations 




Among approximately 5000 SOT patients followed in our transplant program, 57 were VZV-
IgG negative. Of those, 31 met inclusion criteria and were approached (Figure 2). Twenty-
three patients consented to participate, 7 did not consent and 1 patient was not enrolled 
because of a concurrent acute kidney insufficiency under investigation. Every patient enrolled 
was VZV seronegative prior to transplant and had VZV IgG retested at V1 and were 
confirmed IgG negative. All 23 patients completed the study (Figure 2). 
Median age at enrollment was 38 years and median time between SOT and enrollment was 3.8 
years (Table 1). The median interval between the 2 vaccine doses was 2.7 months 
(interquartile range [IQR] 2.3-3.5). Liver transplant recipients were the most frequently 
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triple immunosuppression, whereas 8.7% and 13.0% were on double and single 
immunosuppression, respectively. 
3.2 Humoral immunity 
Anti-gE. In the cohort of 23 patients, median anti-gE levels significantly increased from V1 
to V3 (p=0.001), and V2 to V3 (p<0.001), but not from V1 to V2 (p=0.237) (Figure 3). Three 
patients had baseline serology thresholds above the cut-off as measured by gpELISA, despite 
having negative VZV IgG by ELISA.  Excluding these 3 patients, median anti-gE levels 
showed a similar increase from V1 to V3 (p<0.001), V2 to V3 (p<0.001) but not V1 to V2 
(p=0.449) (Figure S2 http://links.lww.com/TP/C105 ).  In these 20 patients, only 11 (55%) 
had a positive seroresponse to the vaccine. Median anti-gE avidity (n=23) increased from V1 
(0% [IQR 0%-0%]) to V2 (0% [IQR 0%-10%]; p=0.025), V1 to V3 (12% [IQR 0%-60%]; 
p=0.002) and V2 to V3 (p=0.006).  
gpELISA. Median VZV antibody levels by gpELISA significantly increased from V1 to V3 
(p=0.009), and V2 to V3 (p=0.003), but not from V1 to V2 (p=0.162) (Figure 3). There was a 
strong correlation between anti-gE and gpELISA antibodies (r=0.947; p<0.001) after 2 
vaccine doses (Figure S3 http://links.lww.com/TP/C105 ). 
Factors associated with humoral immunity. There was no difference in median anti-gE 
levels at V3 between lung and non–lung transplant recipients (p=0.169). The use of 
prednisone and mycophenolate (analyzed as yes/no variables) was associated with 
significantly lower anti-gE responses (p=0.046 and 0.004 respectively), whereas no 
association was noted with tacrolimus or cyclosporine (data not shown). However, there was 
no correlation between anti-gE levels and the dose of either prednisone (r=0.048; p=0.854) 
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3.3 Cell-mediated immunity 
Median polyfunctional CD4+ T-cells counts significantly increased from V1 (54/106 cells 
[IQR 27-97/106] to V2 (104/106 cells [IQR 47-271/106]; p=0.041), from V2 to V3 (380/106 
cells [IQR 99-1034/106]; p=0.002) and from V1 to V3 (p<0.001) (Figure 4). There was no 
significant increase in median polyfunctional CD8+ T-cells between V1 (43/106 cells [IQR 17-
99/106], V2 (39/106 cells [IQR 24-85/106] and V3 (74/106 cells [IQR 30-133/106] (Figure 4). 
Among polyfunctional CD4+ T-cells, IL-2 and CD40L contributed the most to 
polyfunctionality (Figure S4 http://links.lww.com/TP/C105 ). 
Factors associated with cell-mediated immunity. Lung transplant recipients had lower 
median polyfunctional CD4+ T-cells counts at V3 (99/106 [IQR 64-256]) than other organ 
transplant recipients (540/106 [IQR 207-1350]; p=0.015). The use of individual 
immunosuppressants including prednisone (as a yes/no variable) were not associated with 
VZV-specific cellular immunity (data not shown). However, increasing doses of 
mycophenolate was associated with lower polyfunctional CD4+ T-cell responses at V3 (r=-
0.593; p=0.009). The effect of individual doses of mycophenolate is shown in Figure S5 
http://links.lww.com/TP/C105 . 
Correlation between humoral and cell-mediated immunity. Anti-gE titers and 
polyfunctional CD4 T-cells at V3 were moderately correlated (r=0.515; p=0.014) after the 
second vaccine dose (Figure S6 http://links.lww.com/TP/C105 ). 
3.4 Safety 
The vaccine was overall well-tolerated. Questionnaires were returned after 38/46 vaccine 
doses (83%). Among solicited adverse events, pain at injection site and myalgia were the 
most frequently reported (after 76% and 42% of doses, respectively) (Table 2). Ninety-one 
percent of the adverse events were mild or moderate. All events were self-limited and no 
medical attention was needed. There were 17 unsolicited adverse events that occurred in 10 
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for the following reasons: fever or infectious syndromes (n=3), cardiac (n=2), liver failure 
(n=2, including 1 death), new onset inflammatory bowel disease (n=1) and deep venous 
thrombosis (n=1). The 2 admissions for liver failure happened in the same liver transplant 
patient known prior to enrollment for a failing graft secondary to recurrence of primary 
sclerosing cholangitis. Other adverse events managed in the ambulatory setting were 
infectious (n=4), renal (n=1), ophthalmologic (n=1), chest pain (n=1) and enlarged lymph 
node (n=1). No rejection occurred in the 3 months following vaccination. 
DISCUSSION 
We performed a proof-of-concept study to determine the immunogenicity and safety of 2 
doses of recombinant zoster vaccine in a cohort of VZV seronegative transplant recipients. 
We found that a significant proportion of patients develop gE-specific humoral and cell-
mediated immunity suggesting that this is a viable option for primary vaccination of VZV 
seronegative patients who have a contraindication to live VZV vaccine. The vaccine was also 
well-tolerated, with frequent though mostly mild or moderate adverse events. To our 
knowledge, there are no prior published data on the immunogenicity and safety of RZV in 
VZV-seronegative cohorts. 
Vaccine options for immunocompromised patients that are susceptible to primary varicella are 
limited. Patients can receive live varicella vaccine in the pretransplant period but this has 
generally been avoided since patients need to be put on hold for transplant for 4 weeks after 
each vaccine dose. Recently there has been an effort to select patients posttransplant that are 
on low levels of immunosuppression and could receive live vaccines.17 However, these 
guidelines may not apply to a significant proportion of patients and carries inherent risks 
related to live virus vaccination in immunocompromised patients. Based on 
immunosuppression, almost all of our adult study cohort (22/23) would not meet the criteria 
for safe live-attenuated vaccine administration recently suggested for transplanted children.17 
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immune-competent as well as immunocompromised adults who are VZV-seropositive. In this 
setting, it has good immunogenicity and efficacy to prevent shingles.8-13 However, it is 
unknown whether RZV could potentially prevent primary varicella infection. RZV contains 
recombinant gE protein and is mixed with an adjuvant prior to administration. Glycoprotein E 
plays a critical role in many aspects of the viral life cycle including viral entry into the cell 
and virion assembly.18,19 Therefore, in theory, it can be postulated that humoral immunity to 
gE may prevent primary infection or may mitigate its severity. Although the prevalence of 
VZV-naïve individuals is generally low in the adult transplant population (<5% in the 
literature and 1-2% at our transplant center),20 it is significantly greater in pediatric 
transplantation where immunizations may be missed due to chronic illness.21 
We evaluated humoral immune response to the vaccine using various methods: gE ELISA 
including antibody avidity and gpELISA. Overall, there was a significant increase in 
antibodies although the rise was only significant after the second vaccine dose suggesting that 
at least 2 doses are required for a robust humoral response. Given that just over half the 
patients met the criteria for humoral response, it is possible that more than 2 doses would be 
required in a VZV-naïve immunosuppressed population. Humoral immunity was expressed as 
mean (adjusted) in optical density rather than an antibody concentration since international 
standard sera for these assays were not available. Moreover, correlates of protection for anti-
gE are not defined. Nevertheless, we found that based on our conservative definition of 
vaccine response, more than half the transplant patients had a humoral response. Anti-gE also 
highly correlated with results from gpELISA. The gpELISA is readily available through 
reference laboratories and has greater sensitivity for evaluation of humoral immunity 
postvaricella vaccination than a standard VZV IgG.22 Although not specific to gE, this could 
also potentially be useful for determine response to the subunit zoster vaccine since anti-gE 
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Notably, we found that 3 patients who were VZV IgG seronegative by local testing, had a 
positive baseline gpELISA result.  Even if these patients are excluded, antibody response to 
gE was significant in the remaining cohort.  T-cell immunity also plays a critical role in 
control of herpesviruses. Therefore, we used a VZV gE peptide pool to stimulate PBMCs. 
Interestingly, although CD4+ T-cells significantly increased after vaccination, a CD8+ T-cell 
response was not seen and this finding is in keeping with previous T-cell studies of RZV 
vaccination.10,13 It is possible that this is due to the antigenic stimulus used in the in vitro 
assay and may differ if other antigens such as VZV lysate were used. Interestingly, CD4+ T-
cells responses have been shown to be more important than CD8+ responses in the control of 
varicella.23,24 Baseline T-cell reactivity against gE protein was found in many patients; since 
patients were VZV-naïve, this may be due to crossreactivity of VZV gE epitopes with that of 
HSV-related gE. HSV seropositivity is common in the general population and HSV also 
encodes a gE protein similar to VZV-gE.25  An alternate explanation is T-cell receptor 
promiscuity with response to heterologous antigens.26  Nevertheless, there was significant rise 
in CD4+ T-cell responses postimmunization.   The humoral response had a moderate and 
significant positive correlation with the T-cell response.  
Immunosuppression had an important impact on vaccine responses and the current study 
shows that prednisone and mycophenolate both inhibited anti-gE responses whereas only 
mycophenolate inhibited VZV-specific T-cell responses. Prednisone inhibits antigen 
presentation and mycophenolate is a cell cycle inhibitor that also has a dose-dependent effect 
on humoral and cellular responses to influenza vaccine in transplant recipients.27,28  
RZV contains the ASO1B adjuvant and general concerns have been raised regarding 
enhanced alloimmunity and autoimmunity with adjuvants. We did not find any significant 
rejection episodes that occurred after vaccination; however, most patients were several years 
posttransplant, when the risk of rejection is lower. Anecdotal evidence and small case series 
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could induce the production of donor specific anti-HLA antibodies.29 However, in larger 
samples, these vaccines proved to be safe with regards of the risk of rejection in solid organ 
transplant recipients.30,31 Moreover, in a randomized trial of kidney transplant recipients that 
were given RZV vaccine, there was no increase in risk of rejection compared to placebo.9 We 
did not test for HLA antibodies due to lack of a control group but future studies could 
compare changes in HLA alloantibody in a controlled setting. 
Our study has some limitations. The sample size was relatively small and reflects the small 
numbers of VZV IgG negative transplant recipients at a given transplant center; however, 
were able to demonstrate immunogenicity and safety of the vaccine, albeit in a predominantly 
white population. The concentration of anti-gE was not determined making it difficult to 
compare anti-gE levels to previous immunogenicity studies with RZV. However, correlates of 
protection with anti-gE are not known and we were able to demonstrate a significant rise in 
anti-gE levels after the second dose. Our study was performed in adult transplant recipients 
and further studies in the pediatric population are needed.  
The most important implication of our study is that RZV is a viable option to generate a 
humoral and cell-mediated response and potentially prevent primary varicella in 
immunosuppressed persons who did not receive adequate pretransplant varicella vaccination 
and remain at risk for primary varicella. Further studies will need to determine the efficacy of 
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Figure 1. Study design in terms of vaccine doses and study bloodwork. 
RZV: recombinant zoster vaccine 
Figure 2. Study flowchart.  
SOT: Solid Organ Transplantation; VZV: Varicella-zoster virus; IgG: Immunoglobulin G; 
HIV: Human Immunodeficiency virus; NYD: Not yet determined. 
Figure 3. Evolution of anti-gE (3A), anti-gE avidity (3B) and gpELISA antibody (3C) after 
vaccine doses. 
ELISA: enzyme-linked immunosorbent assay; IgG: immunoglobulin G 
Figure 4. Frequency of antigen-specific cytokine-producing CD4+ (4A) and CD8+ (4B) T-
cells after stimulation with a VZV peptide pool.  
Results are expressed as median number of antigen-specific cytokine-producing CD4+ 
cells/106 CD4+ T-cells (4A) and CD8+ cells/106 CD8+ T-cells (4B).  
SUPPORTING INFORMATION 
Additional supporting information may be found online in the Supporting Information section 
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Table 1. Characteristics of Study Population 
Demographics 
Patients, n  23 
Male, n (%)  11 (47.8) 
Median age at enrollment, yrs (IQR) 38.0 (31.3-55.8) 
Median time since transplant, yrs (IQR) 3.8 (1.4-6.4) 
Race  
White 20 (87.0) 
Black 2 (8.7) 
Asian 1 (4.3) 
    
Organ, n (%)   
Liver  8 (34.8) 
Lunga  7 (30.4) 
Kidney  4 (17.4) 
Combinedb  4 (17.4) 
    
Comorbidities   
Median BMI, kg/m2 (IQR) 23.9 (20.3-29.0) 
 Obesity (BMI>30), n (%) 4 (17.4) 
Diabetes, n (%)  5 (21.7) 
Kidney insufficiency (GFR<60 
mL/min/1.73 m2), n (%) 
9 (39.1) 
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Mycophenolate, n (%) 18 (78.3) 
 Median dose, mg/d (IQR)c 720 (720-1080) 
Cyclosporine, n (%) 4 (17.4) 
 Median trough level, µg/l (IQR) 269 (193-319) 
Tacrolimus, n (%)  19 (82.6) 
 Median trough level, µg/l (IQR) 7.7 (5.0-8.7) 
Prednisone, n (%)  18 (78.3) 
 Median dose, mg/d (IQR) 5 (5-10) 
Azathioprine, n (%) 2 (8.7) 
    
Received in the last 6 months  
ATG   0 (0) 
Methylprednisolone 3 (13.0) 
Basiliximab   1 (4.3) 
IQR: interquartile range; BMI: body mass index; ATG: antithymocyte globulin; GFR: 
glomerular filtration rate 
aTwo lung transplant patients also had a kidney transplant 
bliver/kidney (n=2); kidney/pancreas (n=1); kidney/heart (n=1)  
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Table 2. Frequency of reactions reported during the 7-day post-vaccination period 
Doses 
(N=38) 





   
 Redness 8 (21.1) 2.5 (1.3-3.8) 
    >6cm 1 (2.6) 7 (-) 
    
 Swelling 10 (26.3) 2 (2.0-3.3) 
    >6cm 1 (2.6) 1 (-) 
    
 Pain 29 (76.3) 3 (2-4) 
     Severe 4 (10.5) 1.5 (1-2.8) 
Systemic 
reaction 
   
 Fever >38ºC 1 (2.6) 2 (-) 
    
 Nausea and/or 
vomiting 
3 (7.9) 2 (1-3) 
    Severe 0  
    
 Fatigue 8 (21.1) 1.5 (1-3) 
    Severe 0  
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 Myalgia 16 (42.1) 3 (1.0-4.0) 
    Severe 1 (2.6) 1 
    
 Headache 5 (13.2) 2 (1.0-4.5) 
    Severe 0  
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